Multidimensional Integrated Assessment to Test the Efficacy and Response to Ozanimod in Multiple Sclerosis.
Status:
Recruiting
Trial end date:
2025-01-31
Target enrollment:
Participant gender:
Summary
This is a prospective interventional study with a 12-month follow-up of patients diagnosed
with Multiple Sclerosis. Enrollment includes patients for whom Ozanimod will be prescribed
based on regular clinical practice. It is proposed to integrate the measurements obtained
using multiple instruments, with the aim of analyzing the immunological landscape,
connectivity networks and anatomical traits of neurodegeneration.
Patients will return for imaging and noninvasive electrophysiological studies 3, 6, and 12
months after initiation of therapy. On the same day, blood samples will be taken and
immunological and biochemical tests will be performed.